US5004723038

We assign a fundamental rating of **4** out of 10 to **PHG**. **PHG** was compared to 187 industry peers in the **Health Care Equipment & Supplies** industry. Both the profitability and financial health of **PHG** have multiple concerns. **PHG** has a decent growth rate and is not valued too expensively.

In the past year **PHG** had a positive cash flow from operations.

In multiple years **PHG** reported negative net income over the last 5 years.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -1.58% | ||

ROE | -3.87% | ||

ROIC | N/A |

ROA(3y)1.3%

ROA(5y)2.5%

ROE(3y)2.33%

ROE(5y)5.25%

ROIC(3y)N/A

ROIC(5y)N/A

In the last couple of years the **Operating Margin** of **PHG** has declined.

The **Gross Margin** of **PHG** (**41.00%**) is worse than **64.71%** of its industry peers.

In the last couple of years the **Gross Margin** of **PHG** has remained more or less at the same level.

The **Profit Margin** and **Operating Margin** are not available for **PHG** so they could not be analyzed.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 41% |

OM growth 3Y-40.52%

OM growth 5Y-26.4%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.47%

GM growth 5Y-1.32%

The number of shares outstanding for **PHG** has been reduced compared to 1 year ago.

The number of shares outstanding for **PHG** has been increased compared to 5 years ago.

The Debt to FCF ratio of **PHG** is **4.76**, which is a neutral value as it means it would take **PHG**, **4.76** years of fcf income to pay off all of its debts.

Looking at the **Debt to FCF ratio**, with a value of **4.76**, **PHG** belongs to the top of the industry, outperforming **81.82%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.58 | ||

Debt/FCF | 4.76 | ||

Altman-Z | 1.7 |

ROIC/WACCN/A

WACC6.45%

The **Current ratio** of **PHG** (**1.20**) is worse than **89.84%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.2 | ||

Quick Ratio | 0.78 |

Measured over the past years, **PHG** shows a decrease in **Earnings Per Share**. The EPS has been decreasing by **-2.67%** on average per year.

Looking at the last year, **PHG** shows a small growth in **Revenue**. The Revenue has grown by **0.36%** in the last year.

The **Revenue** has been growing slightly by **0.05%** on average over the past years.

EPS 1Y (TTM)25.49%

EPS 3Y-15.7%

EPS 5Y-2.67%

EPS Q2Q%18.18%

Revenue 1Y (TTM)0.36%

Revenue growth 3Y1.62%

Revenue growth 5Y0.05%

Sales Q2Q%-0.7%

The **Earnings Per Share** is expected to grow by **16.13%** on average over the next years. This is quite good.

Based on estimates for the next years, **PHG** will show a small growth in **Revenue**. The Revenue will grow by **4.56%** on average per year.

EPS Next Y17.07%

EPS Next 2Y13.73%

EPS Next 3Y13.94%

EPS Next 5Y16.13%

Revenue Next Year1.37%

Revenue Next 2Y3.14%

Revenue Next 3Y3.67%

Revenue Next 5Y4.56%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

A **Price/Earnings** ratio of **18.57** indicates a rather expensive valuation of **PHG**.

The **Price/Forward Earnings** ratio is **14.86**, which indicates a correct valuation of **PHG**.

Based on the **Price/Forward Earnings** ratio, **PHG** is valued cheaper than 89.30% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 18.57 | ||

Fwd PE | 14.86 |

Based on the **Enterprise Value to EBITDA** ratio, **PHG** is valued a bit cheaper than the industry average as 74.33% of the companies are valued more expensively.

93.05% of the companies in the same industry are more expensive than **PHG**, based on the **Price/Free Cash Flow** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 13.77 | ||

EV/EBITDA | 24.28 |

The **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

PEG (NY)1.09

PEG (5Y)N/A

EPS Next 2Y13.73%

EPS Next 3Y13.94%

Compared to an average industry **Dividend Yield** of **1.74**, **PHG** pays a better dividend. On top of this **PHG** pays more dividend than 99.47% of the companies listed in the same industry.

Compared to an average S&P500 **Dividend Yield** of **2.33**, **PHG** pays a better dividend.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.15% |

The dividend of **PHG** decreases each year by **-65.46%**.

Dividend Growth(5Y)-65.46%

Div Incr Years0

Div Non Decr Years0

The earnings of **PHG** are negative and hence is the payout ratio. **PHG** will probably not be able to sustain this dividend level.

DP-0.43%

EPS Next 2Y13.73%

EPS Next 3Y13.94%

**KONINKLIJKE PHILIPS NVR- NY**

NYSE:PHG (7/15/2024, 7:04:00 PM)

After market: 26 0 (0%)**26**

**-0.68 (-2.55%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap24.25B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.15% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 18.57 | ||

Fwd PE | 14.86 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)1.09

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -1.58% | ||

ROE | -3.87% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 41% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.62

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.58 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.2 | ||

Quick Ratio | 0.78 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)25.49%

EPS 3Y-15.7%

EPS 5Y

EPS Q2Q%

EPS Next Y17.07%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)0.36%

Revenue growth 3Y1.62%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y